Default company panoramic image

Iron Horse Diagnostics, Inc.

Iron Horse has diagnostics for ALS and TBI/Concussion. The ALS diagnostic is undergoing a final clinical validation with grant funding from NIH & Biogen Idec.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Scottsdale, AZ, USA
  • Currency USD
  • Founded February 2012
  • Employees 6
  • Website

Company Summary

Iron Horse has two diagnostic products in development. The first for ALS/Lou Gehrig’s Disease, will be market ready as a laboratory developed test (LDT) after a final validation study to be completed in 2016 conducted with non-dilutive grant funding from NIH and big Pharma partner Biogen Idec. Our second diagnostic product is for traumatic brain injury and concussion. A $17 BN market with an anticipated market release in 2018.


  • 45c309a8 7ff7 4bc3 9422 a6e48245fa1f

    Dr. Bowser is a Professor and Chair of Neurobiology and a serial entrepreneur. He is co-Founder of Knopp Biosciences, focused on developing drug treatments for neurologic diseases. Knopp signed a parternship deal in 2010 with Biogen Idec for $345 million for a drug targeting ALS (Lou Gehrig’s disease). Dr. Bowser formed Iron Horse Diagnostics in 2012 to market diagnostics and companion biomarkers for ALS and other neurologic diseases.

  • Default avatar
    Gerry Shaw, Ph.D.
    Co-Founder and Scientific Advisor

    Dr. Shaw is President of EnCor Biotechnology and long-time collaborator with Dr. Bowser on the discovery and validation of protein biomarkers for neurodegenerative diseases. EnCor is contracted to generate and purify antibodies used in the diagnostic assays developed and marketed by Iron Horse. This important partnership provides a key advantage for Iron Horse versus other competitors in the field that often rely on multiple antibody sources.

  • 8a3f4a2b 7c74 4ba1 bc9e 088216bf236a
    Chief Scientific Officer

    Dr. Jeromin has industry experience in the vallidation of disease related biomarkers and generation of clinical diagnostic tests. He has worked in the areas of traumatic brain injury and was recently a Director of a Biotechnology company focused on biomarkers for brain injury and disease.

  • Dr. Gundel has extensive industry experience from executive management positions at a number of leading biopharmaceutical companies prior to joining Iron Horse Diagnostics. Most recently Dr. Gundel was President and CEO of Amorfix Life Sciences, Chief Scientific Officer at Heat Biologics, the Vice President and Head of Research at Elusys Therapeutics Inc., and Chief Scientific Officer at Arius Research, Inc.

  • Default avatar
    Michael T. Hull, MBA
    Chief Financial Officer

    Mike has over 20 years of experience in start-ups, derivative and financial product structuring, regulatory compliance, commercialization and grant production in the life science, technology and Healthcare sectors and was a founding board member of the Arizona Angels investment group.


  • Default avatar
    Geoffrey Ossias, Quarles & Brady LLP

Previous Investors

  • Default avatar
    Robert Bowser